The European endometriosis therapeutics market will experience sustained growth in the coming years.Rising awareness about the condition coupled with the anticipated launch of improved products will be the major driving forces in market expansion.
New analysis from Frost & Sullivan (pharma.frost.com), European Endometriosis Therapeutics Market, finds that this market was valued at $365.0 million in 2006 and estimates this to reach $511.6 million in 2013.
If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of the European Endometriosis Therapeutics Market, send an email to Radhika Menon Theodore, Corporate Communications, at rmtheodore@[.]frost.com with your full name, company name, title, telephone number, email address, city, state and country. We will send you the
information through email upon receipt of the above information.
"With a large untreated population, endometriosis remains a considerably underdeveloped market," says Frost & Sullivan Research Analyst Vaibhav Sarvesh. "However, patient awareness about the condition has been increasing, setting the stage for enhanced market penetration."
The projected introduction of novel products with better side effects together with changing raising awareness will help increase adoption levels of endometriosis therapeutics across Europe.
"GnRH Antagonist and progestins with longer treatment periods will be the most important treatment options that will support market expansion," notes Mr. Sarvesh. "Heightened awareness due to information dissemination campaigns, paralleled by the availability of products with enhanced safety profiles will positively impact market growth."
The current lack of efficient and non-invasive diagnostic procedures as well as the negative side effects of existing therapeutics is restraining the market from growing at its real potential. An aging population and restrictive reimbursement policies are further impeding market growth. "Laparoscopy is considered the gold standard for the diagnosis of endometriosis, but this procedure is invasive and costly," adds Mr. Sarvesh. "No new procedures are expected to be launched in the near future, thereby will continue to hinder market growth."
At the same time, the side effect of current treatment options, particularly the effect of some of the drugs on bone density, will pose a major challenge to market expansion until new treatments are introduced.
Considering the large population of untreated patients, increasing awareness will be the key to market growth. Promoting knowledge about the disease coupled with the launch of drugs with fewer side effects will be critical to sustaining market development. Although antagonists are expected to drive the market in the future, success also awaits any innovative therapeutic approach such as the use of progestin modulators.
European Endometriosis Therapeutics Market is part of the Pharmaceutical & Biotechnology Growth Partnership Service, which also includes research in the following markets: European Urinary Incontinence Therapeutics Market, European Blockbusters coming off patent - Opportunities for Generics, and European Osteoarthritis Therapeutics Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.